文献速递脑血管病

基底动脉闭塞血管内治疗与药物治疗:ATTENTION随机临床试验3年结局

Endovascular vs Medical Treatment of Basilar Artery Occlusion: 3-Year Outcomes of the ATTENTION Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

ATTENTION试验3年随访显示,急性基底动脉闭塞患者接受血管内取栓联合最佳药物治疗,3年功能独立(mRS 0-3)比例显著高于单纯药物组,且3年累积死亡率更低;获益在70岁以下患者中明显,70岁及以上未显示治疗效应。

要点

  • 急性基底动脉闭塞取栓的临床获益在3年时仍持续存在。
  • 取栓组3年mRS 0-3达38.4%,药物组18.3%,校正RR 2.05。
  • 取栓组3年累积死亡率55.7%,药物组73.1%,校正RR 0.76。

核心结论

  • 急性基底动脉闭塞血管内取栓的临床获益在3年时仍持续,功能结局显著优于单纯药物治疗且死亡率更低。

研究设计与样本

  • ATTENTION随机临床试验的3年随访扩展分析,开放标签、评估者盲法,中国36家综合卒中中心参与。
  • 共340例症状发作12小时内的急性基底动脉闭塞患者随机分入取栓组或对照组,307例(90.3%)完成3年随访。

主要发现

  • 307例可分析患者中,取栓组78例(38.4%)3年mRS 0-3,对照组19例(18.3%),校正RR 2.05(95%CI 1.35-3.11;P=.001)。
  • mRS分布 favoring 取栓组,校正共同OR 2.60(95%CI 1.53-4.43)。
  • 3年累积死亡率取栓组从90天36.7%(n=83)升至55.7%(n=113),对照组从55.3%(n=63)升至73.1%(n=76),校正RR 0.76(95%CI 0.65-0.89)。
  • 预设亚组分析中,70岁以下患者观察到获益,70岁及以上患者未显示治疗效应。

关键数值与推荐

  • 主要结局为3年mRS 0-3(能行走和自理),取栓组38.4% vs 对照组18.3%,校正RR 2.05(95%CI 1.35-3.11;P=.001)。
  • 3年累积死亡率取栓组55.7% vs 对照组73.1%,校正RR 0.76(95%CI 0.65-0.89)。
  • mRS分布校正共同OR 2.60(95%CI 1.53-4.43)。

临床怎么用

  • 结果支持血管内取栓作为基底动脉闭塞的标准治疗,并支持更广泛实施和及时获得取栓服务。
  • 对70岁以下急性基底动脉闭塞患者,取栓的长期获益证据更明确。

局限性

  • 3年随访中307/340例(90.3%)有可用数据,存在失访。
  • 亚组分析提示70岁及以上患者未显示治疗效应,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Endovascular thrombectomy (EVT) has been established as an effective treatment for acute basilar artery occlusion (BAO) in the short term. However, the durability of these benefits over the long term has not been well characterized. OBJECTIVE: To determine whether the clinical benefits of EVT for acute BAO are sustained at 3 years, with a primary focus on functional outcomes and mortality compared with best medical management alone. DESIGN, SETTING, AND PARTICIPANTS: This study is a 3-year follow-up extension of a multicenter randomized clinical trial conducted between February 2021 and January 2022, with follow-up data collected through January 2025. The study was designed as an open-label, assessor-blinded trial to evaluate the long-term efficacy of EVT. The trial was conducted at 36 comprehensive stroke centers across China, representing a diverse, population-based setting that enhances the generalizability of the results. A total of 340 patients with acute BAO within 12 hours of estimated symptom onset were randomly assigned to the thrombectomy or control group. Eligible participants were adults with imaging-confirmed BAO and without contraindications to endovascular therapy. Of the randomized patients, 307 (90.3%) completed 3-year follow-up-203 in the thrombectomy group and 104 in the control group. INTERVENTIONS: Participants in the thrombectomy group received EVT in combination with best medical management, while the control group received best medical management alone. EVT procedures were performed according to institutional protocols using stent retrievers, aspiration devices, balloon angioplasty, stent deployment, intra-arterial thrombolysis, or combinations of these approaches that were left to the discretion of the treating team. MAIN OUTCOMES AND MEASURES: The primary outcome was a modified Rankin Scale (mRS) score of 0 to 3 at 3 years, representing the ability to walk and perform self-care. Secondary outcomes included a mRS score of 0 to 2, distribution across the mRS score categories, and quality of life. These outcomes were prespecified prior to data analysis. RESULTS: Among 307 patients (median [IQR] age, 68 [59-75]; 211 [69%] male) with available data, an mRS score of 0 to 3 at 3 years was observed in 78 patients (38.4%) in the thrombectomy group and in 19 patients (18.3%) in the control group (adjusted risk ratio, 2.05; 95% CI, 1.35-3.11; P = .001). The distribution of mRS scores favored the thrombectomy group over the control group (adjusted common odds ratio, 2.60; 95% CI, 1.53-4.43). The cumulative 3-year mortality increased from 36.7% (n = 83) at 90 days to 55.7% (n = 113) in the thrombectomy group and 55.3% (n = 63) to 73.1% (n = 76) in the control group (adjusted risk ratio, 0.76; 95% CI, 0.65-0.89). On prespecified subgroup analysis, benefit was observed in patients younger than 70 years; a treatment effect was not demonstrated in patients aged 70 years and older. CONCLUSIONS AND RELEVANCE: At 3 years, the clinical benefit of EVT in patients with acute BAO was durable, with substantially better functional outcomes and reduced mortality compared with medical management. These results reinforce EVT as the standard of care for BAO and support broader implementation and timely access to thrombectomy services. TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2400082236.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hu W, Tao C, Li R, et al. Endovascular vs Medical Treatment of Basilar Artery Occlusion: 3-Year Outcomes of the ATTENTION Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 41460644. doi:10.1001/jamaneurol.2025.5077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。